New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51
December 02, 2016 at 11:33 AM EST
After agreeing to cover Sarepta Therapeutics Inc (NASDAQ: SRPT)’s controversial Duchenne muscular dystrophy drug Exondys 51, ...